Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Bevacizumab/cabozantinib/erlotinib

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Jha P, et al. Identification of EGFR mutations in type II papillary renal cell carcinoma. Cancer Research, Statistics, and Treatment 6 : 457-460, No. 3, Jan 2023. Available from: URL: https://www.crstonline.com/ Jha P, et al. Identification of EGFR mutations in type II papillary renal cell carcinoma. Cancer Research, Statistics, and Treatment 6 : 457-460, No. 3, Jan 2023. Available from: URL: https://​www.​crstonline.​com/​
Metadaten
Titel
Bevacizumab/cabozantinib/erlotinib
Lack of efficacy: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48670-5

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Diazoxide

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Venetoclax

Case report

Temozolomide